{
    "Clinical Trial ID": "NCT00334542",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Simvastatin",
        "  Simvastatin 40 mg for 24-28 weeks"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  History of histologically confirmed breast cancer, meeting 1 of the following staging criteria:",
        "  Ductal carcinoma in situ",
        "  Stage I-III invasive breast cancer",
        "  At least 3 months since completion of all intended local and systemic therapy, including mastectomy or lumpectomy with or without radiotherapy, adjuvant chemotherapy, and/or endocrine therapy",
        "  May have declined recommended treatment provided all treatment intended/agreed upon by the patient and treating physician was completed  3 months ago",
        "  At least 1 healthy intact breast",
        "  No prior radiotherapy or mastectomy",
        "  Prior biopsies allowed",
        "  Any hormone-receptor status",
        "  PATIENT CHARACTERISTICS:",
        "  Female",
        "  Pre- or post-menopausal",
        "  ECOG performance status 0-2",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective nonhormonal contraception",
        "  No active liver disease",
        "  AST and ALT  3 times upper limit of normal",
        "  Creatinine clearance  30 mL/min",
        "  No prior hypersensitivity to any 3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitor or any of its components",
        "  No other concurrent infectious, inflammatory, or autoimmune diseases (at the discretion of principal investigator)",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  No daily alcohol use > 3 standard drinks per day",
        "  Standard drink defined as 10 grams of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor",
        "  No selective estrogen receptor modulator or aromatase inhibitor within the past 3 months",
        "  No hormone replacement therapy (HRT) within the past 3 months",
        "  No prior estrogen and/or progesterone HRT  5 years in duration",
        "  Vaginal estrogen preparations allowed",
        "  No concurrent HRT",
        "  No other cholesterol-lowering drug, including a statin, within the past 3 months",
        "  No concurrent itraconazole, ketoconazole, nefazodone, cyclosporine, HIV protease inhibitors, clarithromycin, erythromycin, mibefradil, carbamazepine, bosentan, chaparral, amiodarone, or verapamil",
        "  No concurrent daily grapefruit juice consumption > 8 ounces per day",
        "  No other concurrent agents or therapies intended to treat or prevent in situ or invasive breast cancer"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline",
        "  [Not Specified]",
        "  Time frame: Baseline and week 24",
        "Results 1: ",
        "  Arm/Group Title: Simvastatin",
        "  Arm/Group Description: Simvastatin 40 mg for 24-28 weeks",
        "  Overall Number of Participants Analyzed: 47",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: mg/dl  hsCRP: -0.15        (-1 to 0)",
        "  Total cholesterol: -54        (-58.5 to -39)",
        "  High-density lipoprotein cholesterol (HDL): -1        (-2 to 3)",
        "  Estrogen (estrone sulfate): -81.5        (-225.5 to -40.5)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/50 (0.00%)"
    ]
}